Anti-interleukin 17 er en ny behandlingsmulighed for patienter med psoriasisgigt
Sammanfattning
Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with comorbidity and decreased quality of life. The current treatment of PsA is non-steroid anti-inflammatory drugs or in more severe cases disease modifying antirheumatic drugs such as methotrexate or leflunomide, but these agents are often inadequately effective. Biologic tumour necrosis factor (TNF)-inhibitors are effective in the treatment of PsA. However, many patients lose efficacy or have an insufficient response to TNF-inhibitors. Biologic agents targeting interleukin-17A have shown encouraging clinical results.